An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib

Fallopian Tube Cancer Clinical Trial

Official title:

A Phase II Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib in Recurrent Platinum Sensitive Ovarian, Peritoneal, and Fallopian Tube Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05887609
• Other study ID #: 22-0384.cc
• Status: Recruiting
• Phase: Phase 2
• Start date: October 3, 2023
• Est. completion date: December 2027

Study information

• Verified date: May 2024
• Source: University of Colorado, Denver
• Contact: Samantha Hopp
• Phone: 3037240131
• Email: samantha.hopp[@]cuanschutz.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The Principal Investigator hypothesizes the combination of MIRV and Olaparib is an effective, and tolerable, maintenance therapy strategy in platinum sensitive recurrent ovarian cancer.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 53
• Est. completion date: December 2027
• Est. primary completion date: April 15, 2026
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 99 Years

Eligibility

Inclusion Criteria:

• Provision to sign and date the consent form

• Stated willingness to comply with all study procedures and be available for the duration of the study

• Be a woman aged =18 years of age

• Patients must have an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1

• Patients must have a confirmed diagnosis of high-grade serous or endometrioid EOC, primary peritoneal cancer, or fallopian tube cancer

• Patients must have platinum-sensitive disease defined as radiographic progression greater than 6 months from last dose of most recent platinum therapy

• Patients must have had documented complete or partial response, or stable disease, as defined by RECIST 1.1, from last line of platinum therapy

• Patients must have available archival tissue block or slides to confirm FRalpha positivity

• Patients' tumor must have FRalpha high or medium expression

• Prior anticancer therapy:

• Patients must have received at least one prior platinum-based chemotherapy regimen for platinum sensitive recurrent disease.

• Most recent prior chemotherapy regimen must have consisted of at least 4 completed cycles and no more than 8 completed cycles

• Most recent prior chemotherapy regimen must have been platinum based

• Patients must have had testing for BRCA mutation (tumor or germline) and, if positive, must have received a prior PARP inhibitor as either treatment or maintenance therapy

• Neoadjuvant +/- adjuvant therapies are considered 1 line of therapy

• Maintenance therapy (eg, Bevacizumab, PARP inhibitors) will be considered part of preceding line of therapy (ie, not counted independently)

• Therapy changed due to toxicity in the absence of progression will be considered part of the same line (ie, not counted independently)

• Hormonal therapy will be counted as a separate line of therapy unless it was given as maintenance

• Patients must have adequate hematologic, liver, and kidney function as defined as:

• Absolute neutrophil count (ANC) = 1.5 x 109/L (1500/µL)

• Platelet count = 100 x 109/L (100,000 µL)

• Hemoglobin = 10.0 g/dL with no blood transfusion in the past 28 days

• Serum creatinine = 1.5 x upper limit of normal (ULN)

• Patients must have creatinine clearance estimated of =51 mL/min using the Cockcroft-Gault equation or based on a 24 hour urine test

• Aspartate aminotransferase (AST)(Serum Glutamic Oxaloacetic Transaminase (SGOT)) and alanine aminotransferase (ALT) (Serum Glutamic Pyruvate Transaminase (SGPT)) = 2.5 x ULN unless liver metastases are present in which case they must be = 5x ULN

• Serum bilirubin = 1.5 x ULN (patients with documented diagnosis of Gilbert syndrome are eligible if total bilirubin < 3.0 x ULN)

• Serum albumin = 2 g/dL

Exclusion Criteria:

• Patients with clear cell, mucinous, sarcomatous, low grade/borderline, germ cell, or sex-cord stromal type ovarian tumor

• Patients who have progressed through most recent chemotherapy regimen. Stable disease (SD) is permissible.

• Patients receiving any systemic chemotherapy or radiotherapy (except for palliative reasons) within 3 weeks prior to study treatment

• Patients with active or chronic corneal disorders, history of corneal transplantation, or active ocular conditions require ongoing treatment/monitoring, such as uncontrolled glaucoma, wet age-related macular degeneration requiring intravitreal injections, active diabetic retinopathy with macular edema, macular degeneration, presence of papilledema, and/or monocular vision

• Patients with myelodysplastic syndrome/acute myeloid leukemia or with features suggestive of MDS/AML.

• Patients considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection. Examples include, but are not limited to:

• Uncontrolled major seizure disorder

• Unstable spinal cord compression

• Any psychiatric disorder that prohibits obtaining informed consent.

• Active hepatitis B or C infection (whether or not on active antiviral therapy)

• Immunocompromised patients, e.g., patient who are known to be serologically positive for human immunodeficient virus(HIV)

• Active cytomegalovirus infection

• Any other concurrent infectious disease requiring IV antibiotics within 2 weeks prior to the first dose of MIRV

• Patients with a history of multiple sclerosis (MS) or other demyelinating disease and/or Lambert-Eaton syndrome (paraneoplastic syndrome)

• Patients with clinically significant cardiac disease including, but not limited to, any of the following

• Myocardial infarction = 6 months prior to first dose

• Uncontrolled ventricular arrhythmia, recent (within 3 months)

• Superior vena cava syndrome

• Unstable angina pectoris

• Uncontrolled congestive heart failure (New York Heart Association > class II)

• Uncontrolled = Grade 3 hypertension (per CTCAE)

• Uncontrolled cardiac arrhythmias

• Patients with a history of hemorrhagic or ischemic stroke within 6 months prior to enrollment

• Patients with a history of cirrhotic liver disease (Child-Pugh Class B or C)

• Patients with a previous clinical diagnosis of noninfectious interstitial lung disease (ILD) or Extensive interstitial bilateral lung disease on High Resolution Computed Tomography (HRCT) scan , including noninfectious pneumonitis

• Persistent toxicities (>Common Terminology Criteria for Adverse Event (CTCAE) grade 2) caused by previous cancer therapy, excluding alopecia

• Patients requiring use of folate-containing supplements (eg, folate deficiency)

• Concomitant use of known strong CYP3A inhibitors (eg. itraconazole, telithromycin, clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir) or moderate CYP3A inhibitors (eg. ciprofloxacin, erythromycin, diltiazem, fluconazole, verapamil). The required washout period prior to starting study treatment is 2 weeks.

• Concomitant use of known strong (eg. phenobarbital, enzalutamide, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St John's Wort ) or moderate CYP3A inducers (eg. bosentan, efavirenz, modafinil). The required washout period prior to starting study treatment is 5 weeks for enzalutamide or phenobarbital and 3 weeks for other agents.

• Patients with prior hypersensitivity to monoclonal antibodies (mAb)

• Previous allogenic bone marrow transplant or double umbilical cord blood transplantation (dUCBT).

• Women who are pregnant or breastfeeding, and who do not agree to use a highly effective contraceptive method(s) while on study drug and for at least 3 months after the last dose of MIRV. Females of childbearing potential must have a negative serum pregnancy test within 72 hours of study entry. Refer to section 6.9.6 for details.

• Patients who received prior treatment with MIRV or other FRa- targeting agents

• Patients with duodenal stent or other GI disorder/defect that would interfere with absorption of oral medication

• Includes patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication

• Patients with known untreated or symptomatic central nervous system (CNS) metastases

• Patients with a history of other malignancy within 3 years prior to enrollment

• Note: patients with tumors with a negligible risk for metastasis or death (eg, adequately controlled basal-cell carcinoma or squamous-cell carcinoma of the skin, or carcinoma in situ of the cervix or breast) are eligible

• Prior known hypersensitivity reaction to study drugs and/or any of their excipients

• Minor or major surgical procedure within 2 weeks of starting study treatment and patients must have recovered from any effects of any major surgery.

• Inability to comply with study and follow-up procedures

• Patients deemed otherwise clinically unfit for clinical trial per investigators discretion

Related Conditions & MeSH terms

• Fallopian Tube Cancer
• Fallopian Tube Neoplasms
• Ovarian Neoplasms
• Ovary Cancer
• Peritoneal Cancer

Intervention

Drug:
• Mirvetuximab Soravtansine
is an antibody-drug conjugate (ADC) that consists of a high affinity humanized monoclonal antibody against folate receptor a (FRa, the protein product of the folate receptor 1 [FOLR1] gene) that is conjugated to a cytotoxic maytansinoid by the hindered disulfide succinimidyl 4-(pyridine-2-yl)disulfanyl)-2-sulfo-butyrate linker (sulfo-SPDB).
• Olaparib
Olaparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1, PARP2, and PARP3. PARP enzymes are involved in normal cellular functions, such as DNA transcription and DNA repair.

Locations

Country	Name	City	State
United States	University of Colorado Hospital	Aurora	Colorado

Sponsors (2)

Lead Sponsor	Collaborator
University of Colorado, Denver	ImmunoGen, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To measure progression free survival (PFS) with the use of MIRV combined with Olaparib in women with recurrent platinum sensitive ovarian, peritoneal, and fallopian tube cancer.	PFS will be defined as the time from first dose of MIRV and Olaparib until investigator-assessed radiologic PD or death, whichever occurs first	Through study completion, average of 12 months
Secondary	To evaluate safety and tolerability of MIRV combined with Olaparib by Adverse Events as measured by CTCAE v 5.0	The team will use treatment-emergent adverse events (TEAEs) and laboratory test results, physical examination, or vital signs to determine AEs as described by CTCAE v5.0	Through study completion, average of 12 months
Secondary	Determine Overall Response Rate	Defined by confirmed best response of CR or PR as assessed by the investigator	Through study completion, average of 12 months
Secondary	Determine Duration of Response	Defined as the time from initial investigator-assessed response (CR or PR) until progressive disease (PD) as assessed by the investigator	Through study completion, average of 12 months
Secondary	Determine Overall Survival	Defined as the time from first dose of MIRV and Olaparib until death	Up to 5 years